Beta
Trial Radar KI
Die klinische Studie NCT07491159 für Kolorektalkrebs ist aktiv, nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study Phase 1, Phase 2 106 Immuntherapie Gezielte Therapie Kombinationstherapie Gesamtüberleben

Aktiv, nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07491159 untersucht Behandlung im Zusammenhang mit Kolorektalkrebs. Diese interventionsstudie der Phase 1 Phase 2 hat den Status aktiv, nicht rekrutierend und startete am 1. Juli 2023. Es ist geplant, 106 Teilnehmer aufzunehmen. Durchgeführt von Medizinische Universität Tianjin wird der Abschluss für 30. Dezember 2026 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 24. März 2026 aktualisiert.
Kurzbeschreibung
Colorectal cancer (CRC) is the fourth leading cause of cancer death worldwide, claiming approximately 900,000 lives annually. In China, CRC has become one of the top three most common cancers, with about 555,000 new cases and 286,000 deaths reported in 2020.

For patients with advanced metastatic colorectal cancer (mCRC), chemotherapy remains the main treatment approach. While first and second-line treatments have im...

Mehr anzeigen
Offizieller Titel

Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential Trifluridine/Tipiracil(TAS-102) Based Regimen in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study

Erkrankungen
Kolorektalkrebs
Weitere Studien-IDs
  • CRC later-line
NCT-Nummer
NCT07491159
Studienbeginn (tatsächlich)
2023-07-01
Zuletzt aktualisiert
2026-03-24
Studienende (vorauss.)
2026-12-30
Geplante Rekrutierung
106
Studientyp
Interventionsstudie
PHASE
Phase 1
Phase 2
Status
Aktiv, nicht rekrutierend
Stichwörter
fruquintinib
Trifluridine/tipiracil
Microsatellite Stable
metastatic colorectal cancer
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellFruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
Fruquintinib plus immunocheckpoint inhibitor plus trifluridine/tipiracil
ExperimentellFruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Fruquintinib plus immunocheckpoint inhibitor followed by trifluridine/tipiracil plus bevacizumab
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
RP2D
Recommended phase 2 dose
From enrollment to the end of treatment at 4 week
Overall Survival (OS)
Time from randomization/enrollment to death from any cause
Up to 36 months
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Progress-free Survival (PFS)
Time from randomization/enrollment to first documented disease progression (per RECIST v1.1) or death from any cause, whichever occurs first
Assessed every 8 weeks, up to 12 months
Objective Response Rate (ORR)
The proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) as their best overall response, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Tumor assessments performed at baseline, then every 8 weeks (±7 days) from the date of first dose until radiographic disease progression or death, assessed up to approximately 12 months
Duration of Response (DoR)
Time from first documented response (CR/PR) to disease progression or death
Up to 12 months
Incidence of AEs
Number and percentage of participants experiencing adverse events graded by NCI-CTCAE v5.0
by NCI-CTCAE v5.0. From first dose up to 30 days after last dose
Incidence of SAEs
Number and percentage of participants experiencing serious adverse events
From informed consent up to 30 days after last dose
Number of participants with Laboratory abnormalities
Incidence of clinically significant laboratory parameter changes per NCI-CTCAE v5.0
From baseline up to 30 days after last dose
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
  • Fully informed about this study and voluntarily signed the informed consent form;
  • Age 18-75 years (inclusive);
  • Histologically confirmed unresectable metastatic colorectal cancer;
  • Confirmed pMMR (proficient mismatch repair) status without protein loss, as determined by:PCR testing showing microsatellite stable (MSS) or low microsatellite instability (MSI-L), OR Immunohistochemistry (IHC) demonstrating intact DNA mismatch repair (MMR) protein expression (including MLH1, MSH2, MSH6, and PMS2);
  • Failed or intolerant to two prior lines of standard systemic therapy for metastatic colorectal cancer;
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
  • Body Mass Index (BMI) ≥18 kg/m²;
  • Life expectancy ≥3 months;
  • Adequate organ function as defined below (no blood components or growth factors allowed within 14 days prior to enrollment):
  • Hematologic Function:

Absolute neutrophil count (ANC) ≥1.5×10⁹/L; White blood cell count (WBC) ≥4.0×10⁹/L; Platelet count ≥100×10⁹/L; Hemoglobin ≥90 g/L; -Hepatic Function: Total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5×ULN;

-Renal Function: Blood urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN; Creatinine clearance (CCr) ≥50 mL/min;

-Cardiac Function: Left ventricular ejection fraction (LVEF) ≥50%; QT interval corrected by Fridericia's formula (QTcF) <470 ms;

-Coagulation Function: International normalized ratio (INR) ≤1.5×ULN; Activated partial thromboplastin time (APTT) ≤1.5×ULN;

  • Women of childbearing potential must use effective contraception;
  • Good compliance and willing to cooperate with follow-up visits.

  • Unable to comply with the study protocol or study procedures;
  • Prior treatment with TAS-102 (trifluridine/tipiracil);
  • Prior treatment with VEGFR inhibitors;
  • Prior treatment with immune checkpoint inhibitors;
  • Concurrent use of any other investigational drugs, or participation in another clinical trial with investigational drug treatment within 4 weeks prior to enrollment;
  • Vaccination with inactivated vaccines within 4 weeks prior to enrollment or planned vaccination during the study period;
  • Major surgery, severe traumatic injury, fracture, or ulcer within 4 weeks prior to enrollment;
  • Blood transfusion, blood products, or hematopoietic factors (such as albumin, granulocyte colony-stimulating factor \[G-CSF\], etc.) within 28 days prior to enrollment;
  • Alcohol or drug abuse within 4 weeks prior to enrollment;
  • Any factors affecting oral drug administration;
  • Concurrent presence of any of the following conditions:
  • Uncontrolled hypertension, coronary artery disease, arrhythmia, or heart failure;
  • Uncontrolled severe concurrent infection resulting in disability;
  • Proteinuria ≥2+ (1.0 g/24 h);
  • Evidence or history of bleeding tendency within 2 months prior to enrollment, regardless of severity;
  • Arterial/venous thromboembolic events within 12 months prior to first treatment, such as cerebrovascular accident (including transient ischemic attack), etc.;
  • Acute myocardial infarction, acute coronary syndrome, or coronary artery bypass grafting (CABG) within 6 months prior to first treatment;
  • Fracture or long-term unhealed wounds;
  • Coagulation dysfunction, bleeding tendency, or currently receiving anticoagulant therapy;
  • Evidence of central nervous system (CNS) metastasis, or accompanied by severe malignant pleural effusion or ascites;
  • Other malignancies within 5 years prior to enrollment, except for basal cell or squamous cell carcinoma of the skin after curative surgery, or carcinoma in situ of the cervix;
  • Active autoimmune disease or history of autoimmune disease within 4 weeks prior to enrollment;
  • Prior allogeneic bone marrow transplantation or organ transplantation;
  • Known hypersensitivity to study drugs or any of their excipients;
  • Unresolved toxicities greater than CTCAE v5.0 Grade 1 from prior anti-cancer therapy, excluding alopecia, lymphopenia, and oxaliplatin-induced neurotoxicity ≤Grade 2;
  • Any other disease, clinically significant metabolic abnormality, physical examination abnormality, or laboratory abnormality that, in the investigator's judgment, provides reasonable suspicion that the patient has a condition unsuitable for the use of the study drug (e.g., epileptic seizures requiring treatment), or that would affect the interpretation of study results, or would place the patient at high risk;
  • Pregnant or breastfeeding women;
  • Any patient deemed unsuitable for enrollment in this study by the investigator.
Tianjin Medical University Cancer Institute and Hospital logoMedizinische Universität Tianjin378 aktive klinische Studien zum Erkunden
Keine Kontaktdaten vorhanden
1 Studienstandorte in 1 Ländern

Tianjin Municipality

Tianjin Cancer Hospital, Tianjin, Tianjin Municipality, 300202, China